FLUMIST QUADRIVALENT: payments to doctors
Payments that named FLUMIST QUADRIVALENT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6.1M
- Providers
- 5,560
- Transactions
- 7,307
- Average per transaction
- $840
The per-transaction average — $840 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,560 providers the average total is $1,104, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $6,106,981 | 99.5% |
| Astrazeneca UK Limited | $30,730 | 0.5% |
| Acerta Pharma LLC | $227 | 0.0% |